コメント (10)
トラックバックは利用できません。
Diflucan is not first-line for invasive aspergillosis under any circumstances.
Can be used for chronic suppressive therapy in recurrent mucosal candidiasis.
Diflucan exhibits fungistatic, not fungicidal, activity against most susceptible yeasts.
Diflucan can be used for prolonged periods in certain endemic mycoses.
A paradigm for how a single molecule can transform the management of a wide range of fungal diseases.
Primary renal excretion necessitates dose adjustment in patients with renal impairment.
Fungal cell membrane alterations, like increased chitin, can contribute to resistance.
Its generic availability has dramatically reduced treatment costs globally.
Protein binding is relatively low (~12), contributing to good tissue distribution.
Diflucan penetration into the CSF is excellent, a key pharmacological advantage.
Diflucan is not first-line for invasive aspergillosis under any circumstances.
Can be used for chronic suppressive therapy in recurrent mucosal candidiasis.
Diflucan exhibits fungistatic, not fungicidal, activity against most susceptible yeasts.
Diflucan can be used for prolonged periods in certain endemic mycoses.
A paradigm for how a single molecule can transform the management of a wide range of fungal diseases.
Primary renal excretion necessitates dose adjustment in patients with renal impairment.
Fungal cell membrane alterations, like increased chitin, can contribute to resistance.
Its generic availability has dramatically reduced treatment costs globally.
Protein binding is relatively low (~12), contributing to good tissue distribution.
Diflucan penetration into the CSF is excellent, a key pharmacological advantage.